BackApimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Total Liabilities

Track Apimeds Pharmaceuticals US's total liabilities ($21M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$21.18M
↑ 2517.45% YoYΔ $20.37M vs prior year quarter

Peer trimmed avg / median

Loading

Apimeds Pharmaceuticals US Total Liabilities History

Loading

Apimeds Pharmaceuticals US vs. peers: Total Liabilities Comparison

Loading

Apimeds Pharmaceuticals US Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Apimeds Pharmaceuticals US (APUS) FAQ

Apimeds Pharmaceuticals US (APUS) currently reports a total liabilities of $21M as of June 2026. That compares with $810K in the prior-year period — up 2517.4% year over year. Use the charts on this page to explore Apimeds Pharmaceuticals US's total liabilities history and peer comparisons.

Apimeds Pharmaceuticals US's total liabilities increased from $810K to $21M — a 2517.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $21M in total liabilities as of June 2026. That compares with $810K in the prior-year period — up 2517.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.